Clinical trials: Metastatic Renal Cell Carcinoma (mRCC)
Metastatic Renal Cell Carcinoma
Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma
Phase 2 single arm study that evaluated the addition of metformin to nivolumab in pre-treated metastatic renal cell carcinoma (mRCC) patients.
- Trial name
- NivoMet (NCT06884683)
- Testing
- Metformin
- Where
- 2 sites in Italy
- Volunteers
- 12 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Renal Cell Carcinoma
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
- Trial name
- NCT01223027
- Testing
- Dovitinib, Sorafenib
- Where
- 199 sites in United States, Argentina and 25 more
- Volunteers
- 564 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cancer
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma
The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT) for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC) undergoing antiangiogenetic therapy (AAT) with…
- Trial name
- NCT02086734
- Testing
- Perfusion-CT
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Renal Cancer Cell
Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
The study aims to evaluate the efficacy of a third TKI after two previous lines of therapy with TKIs, in terms of median progression free survival (mPFS), in patients affected by metastatic renal cancer cell.
- Trial name
- TOKIO (NCT03456401)
- Testing
- Sorafenib or Sunitinib
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Renal Cell Carcinoma
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases.
- Trial name
- NCT02406521
- Testing
- Pazopanib, Sorafenib, Radium-223
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Kidney Cancer, Renal Cell Carcinoma Metastatic
TDM for Optimized Outcome in Patients With mRCC.
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity, Drug Side Effect
- Trial name
- NCT04659343
- Testing
- Measurement of concentration of active metabolite in cancer treatment.
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Niels Fristrup
Metastatic Renal Cell Carcinoma
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101 in combination with bevacizumab compared to…
- Trial name
- NCT02187302
- Testing
- CRLX101, Bevacizumab, Standard of Care (Investigator Choice)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 115 people
- Sponsor
- NewLink Genetics Corporation
Kidney Cancer
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells.
- Trial name
- NCT00085436
- Testing
- Aldesleukin,, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metastatic Renal Cell Carcinoma
Sutent Rechallenge In mRCC Patients
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
- Trial name
- RESUME (NCT01827254)
- Testing
- sunitinib: observational study
- Where
- 18 sites in France
- Volunteers
- 61 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
The goal is to study the impact of functional MRI and CT evaluation of changes in tumor vessels induced by anti-angiogenic treatment in patients with metastatic RCC.
- Trial name
- REMISCAN (NCT00842790)
- Where
- France
- Volunteers
- 107 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Cell Carcinoma
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial).
- Trial name
- NCT01224288
- Testing
- Perfusion CT scan
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
This phase II trial tests how well zanzalintinib and MO-03 works for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing…
- Trial name
- NCT07578025
- Testing
- Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- City of Hope Medical Center
RCC
A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)
TKI monotherapy or TKI/IO combination therapy is the standard first-line treatment for low- and intermediate-risk advanced renal cell carcinoma (RCC).
- Trial name
- NCT07324876
- Where
- China
- Volunteers
- 860 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Renal Cell Carcinoma (mRCC)
A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor
This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib).
- Trial name
- OSAT (NCT01390519)
- Testing
- everolimis
- Where
- 3 sites in Norway
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cell Carcinoma (mRCC)
International Multicentric Study ARON-1
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.
- Trial name
- NCT05287464
- Testing
- pembrolizumab plus axitinib
- Where
- Italy
- Volunteers
- 1,220 people
- Sponsor
- Hospital of Macerata
Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic).
- Conditions
- Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma
- Trial name
- NCT01767636
- Testing
- Pazopanib Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Metastatic Renal Cell Carcinoma
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
This is an observational, retrospective, multicenter study aimed to compare the toxicity of Nivolumab in patients with metastatic renal cell carcinoma treated in line II and III stratified into 3 patient groups: patients with…
- Trial name
- RI-NIVO (NCT07117409)
- Where
- Italy
- Volunteers
- 81 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Metastatic Renal Cell Carcinoma
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including…
- Trial name
- ODYSSEY RCC (NCT04919122)
- Where
- 14 sites in United States
- Volunteers
- 468 people
- Sponsor
- Duke University
Carcinoma, Renal Cell
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)
- Trial name
- NCT00569946
- Testing
- AG-013736
- Where
- 18 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).
- Trial name
- CABRAMET (NCT03967522)
- Testing
- Cabozantinib
- Where
- 12 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Leon Berard